Imagine a world where tuberculosis (TB), a disease that silently infects one in four people globally, could be eradicated with a simple breath. Sounds like science fiction, right? But what if an inhaled vaccine could make this a reality? While TB has been largely wiped out in wealthier nations, it remains a devastating global health crisis, claiming 1.5 million lives annually. Here’s the shocking part: the current vaccine, Bacillus Calmette-Guérin (BCG), fails to protect adults from the most common form of TB—pulmonary TB. And this is the part most people miss: even though BCG works well in children, its effectiveness mysteriously wanes in adolescence and adulthood, leaving scientists puzzled. But here’s where it gets controversial: could tweaking the vaccine’s delivery method or making it more potent be the game-changer we’ve been waiting for?
Associate Professor Andreas Kupz, a leading researcher at James Cook University’s Australian Institute of Tropical Health and Medicine, believes so. For over a decade, he’s been exploring why BCG falls short and how we can do better. In a groundbreaking study (https://www.mucosalimmunology.org/article/S1933-0219(25)00054-6/fulltext), his team discovered that inhaling a more potent version of BCG activates specialized cells in the lungs, training the immune system to fight TB more effectively. This approach, known as mucosal delivery, could be the key to long-term protection—but it’s not without challenges. Balancing safety and potency is a delicate dance, and human trials are still in their early stages.
Here’s the bold question: Are we willing to rethink how we deliver vaccines to tackle one of the world’s deadliest diseases? Professor Kupz argues that improving BCG, rather than starting from scratch, might be our best bet. With its 4,000 proteins, BCG is a complex powerhouse compared to newer mRNA or protein vaccines, which often target just a handful. But why does delivery matter so much? A study in Nature (https://www.nature.com/articles/s41586-019-1817-8) revealed that injecting BCG directly into the bloodstream of primates offered near-perfect protection—a finding that, while impractical for humans, highlights the importance of how we administer vaccines.
And this is where it gets even more intriguing: In the 1920s, BCG was originally given orally, but a tragic incident in Lübeck (https://pmc.ncbi.nlm.nih.gov/articles/PMC9488810/) shifted its use to intradermal injections. Now, researchers are revisiting mucosal delivery—through the nose or lungs—which has shown promising results in animals. Trials at Oxford University are testing how safe and effective inhaled BCG is in humans, but progress is slow. The COVID-19 pandemic, while raising awareness of respiratory diseases, also disrupted TB treatment and research, leading to a rise in deaths and drug-resistant strains.
TB isn’t just a medical issue—it’s a social and economic one. The World Health Organization calls it a disease of poverty, disproportionately affecting marginalized communities. In Australia, First Nations people face TB infection rates 5-6 times higher than non-Indigenous Australians (https://gh.bmj.com/content/4/6/e001794). Globally, multi-drug resistant TB is on the rise, with hotspots like Papua New Guinea posing biosecurity risks to neighboring regions. Is it our moral duty to prioritize TB research and ensure equitable access to better vaccines?
Professor Kupz’s team is already developing modified BCG strains that boost immunity without increasing risk, but funding remains a hurdle (https://theconversation.com/tuberculosis-kills-as-many-people-each-year-as-covid-19-its-time-we-found-a-better-vaccine-151590). The solution, he says, lies in making mucosal vaccines safe for mass use. But here’s the ultimate question: Will we act boldly enough to end TB’s century-long reign, or will it remain a silent killer for generations to come? Let’s discuss—what do you think is the most urgent step in tackling TB? Share your thoughts below!
